Cancer News and Research

Latest Cancer News and Research

Wellcare faces allegations about director's resignation; Wellpoint confronts reports regarding breast cancer recissions

"A prominent director at WellCare Health Plans Inc. resigned Wednesday and raised questions about accounting practices at the Medicare and Medicaid company. Regina Herzlinger, the head of the board's audit committee and a professor of business administration at Harvard Business School, said internal audits found WellCare overbilled the Illinois Medicaid program by $1 million in 2009 and potentially overcharged states for almost $500,000 worth of maternity care."

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

A first step in the long road to health reform

Australia provides good health care to the majority of its citizens most of the time and compares well with like countries. The capacity for illness to destroy families financially, seen in the US and in many less economically advanced countries where governments make small or no contributions to the cost of health care, is much diminished by Medicare, public hospitals and subsidised pharmaceuticals.

27 Apr 2010

NHS funding a major issue in the coming election

The state of the British economy has made the cut backs in NHS funding a major issue in the coming election. However no matter what the posturing is right now, and no politician wants to be seen making cuts here, there may be no other viable alternatives. No matter who forms the government after 6th May, they will be under great strain to keep their earlier promises of no health fund cuts.

27 Apr 2010

General Dynamics Information Technology awarded task order to support HHS' CMS

General Dynamics Information Technology's VIPS business sector, a business unit of General Dynamics, has been awarded a task order to support the Department of Health and Human Services' Centers for Medicare and Medicaid Services.

26 Apr 2010

Huntington Hospital integrates new electronic order set solution to CPOE system

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Huntington Hospital has selected ProVation Order Sets, powered by UpToDate Decision Support, to automate the creation, deployment and maintenance of evidence-based order sets.

26 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Today's opinions: Health overhaul reflects history of government intervention; Importance of repairing clinical trials system; Stopping Medicare fraud

The system's opacity gives insurers the upper hand in debates over government payment rates (Austin Frakt, 4/26).

26 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

The Frost Group agrees to make investment in ChromaDex

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, announced today The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex.

26 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Cancer News and Research

Latest Cancer News and Research

Wellcare faces allegations about director's resignation; Wellpoint confronts reports regarding breast cancer recissions

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

A first step in the long road to health reform

NHS funding a major issue in the coming election

General Dynamics Information Technology awarded task order to support HHS' CMS

Huntington Hospital integrates new electronic order set solution to CPOE system

ERCC1 Analysis guides patient treatment decisions

Today's opinions: Health overhaul reflects history of government intervention; Importance of repairing clinical trials system; Stopping Medicare fraud

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

The Frost Group agrees to make investment in ChromaDex

Caltech biologists offer new insight into causes of IBD and colon cancer

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

OICR makes equity investments in three promising Ontario technologies

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Researchers synthesize metal compounds that can be effective in treatment of cancer

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in